Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Chemical Works of Gedeon Richter's Debt-to-EBITDA or its related term are showing as below:
BUD:RICHTER'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07 Med: 0.1 Max: 0.36
Current: 0.12
During the past 13 years, the highest Debt-to-EBITDA Ratio of Chemical Works of Gedeon Richter was 0.36. The lowest was 0.07. And the median was 0.10.
BUD:RICHTER's Debt-to-EBITDA is ranked better than 85.04% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs BUD:RICHTER: 0.12
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Chemical Works of Gedeon Richter Debt-to-EBITDA Related Terms
Chemical Works of Gedeon Richter Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter Debt-to-EBITDA Chart
BUD:RICHTER vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Chemical Works of Gedeon Richter (BUD:RICHTER) has a Debt-to-EBITDA of 0.10 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chemical Works of Gedeon Richter. This is near median its historical median of 0.10. Over the past decade, Chemical Works of Gedeon Richter's Debt-to-EBITDA has ranged from 0.07 to 0.36. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #102 out of 682 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is Chemical Works of Gedeon Richter's Debt-to-EBITDA too high?
Chemical Works of Gedeon Richter's current Debt-to-EBITDA of 0.10 is near median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.36. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Chemical Works of Gedeon Richter's value of 0.10 is 93.9% below this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #102 out of 682 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #102 out of 682 companies for Debt-to-EBITDA. This places Chemical Works of Gedeon Richter in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.63. Chemical Works of Gedeon Richter's value of 0.10 is 93.9% below this benchmark. Historically, Chemical Works of Gedeon Richter's own Debt-to-EBITDA has ranged from 0.07 to 0.36 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 1.63, Chemical Works of Gedeon Richter has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current Debt-to-EBITDA of 0.10 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chemical Works of Gedeon Richter. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current Debt-to-EBITDA is 0.10, which is near median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (BUD:RICHTER) is currently considered Modestly Overvalued. The stock's GF Value™ is Ft11,589.93, compared to a current price of Ft13,040.00 — trading 12.5% above its estimated fair value. The current Debt-to-EBITDA is 0.10, which is near median its 10-year median of 0.10 and 93.9% below the Drug Manufacturers industry median of 1.63. Chemical Works of Gedeon Richter's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (BUD:RICHTER), the current Debt-to-EBITDA is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (BUD:RICHTER) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of Ft13,040.00 is trading 12.5% above its estimated GF Value™ of Ft11,589.93.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for BUD:RICHTER:
Debt-to-EBITDA: 0.10 (near median its 10-year median of 0.10)
GF Value™: Ft11,589.93 vs. price of Ft13,040.00 (12.5% above fair value)
Industry Position: 93.9% below the Drug Manufacturers median (#102 of 682)
No single metric tells the full story. See the BUD:RICHTER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
100GF Score
Get the complete analysis for BUD:RICHTER
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:RICHTER has been successfully added to your 
